Edit an article: Wernicke Encephalopathy

You do not have permission to edit this page, for the following reasons:

You are not allowed to execute the action you have requested.
You must confirm your email address before editing pages. Please set and validate your email address through your user preferences.

Original article author(s) EyeWiki username.

Additional contributor (who has not actually edited this page)

Select one or more categories for this page.

Articles
- Cataract/Anterior Segment
- Cornea/External Disease
- Glaucoma
- Miscellaneous
- Neuro-ophthalmology/Orbit
- Ocular Trauma
- Oculoplastics/Orbit
- Oncology/Pathology
- Pediatric Ophthalmology/Strabismus
- Refractive Management/Intervention
- Retina/Vitreous
- Techniques
- Uveitis

Reviewers

Enter the name of the assigned editor for this page.
Enter the name of the reviewer for this page.
Enter the date this page was reviewed.
Select the status of this page.

Local Videos

Meta Description

Enter a short description of the article. Used to generate the page's meta description tag.

Article Text

Edit article text below. You can save this page without filling in all of the sections and come back to it later.

{{Infobox disease | Name = {{PAGENAME}} | DiseasesDB = | ICD9 = | ICD10 ={{ICD10|E|51|2}} | OMIM = 277730 | MeshID = D014899 | MedlinePlus = 000771 }} Wernicke Encephalopathy = Disease Entity = == Disease == Wernicke Encephalopathy (WE) is an acute neurologic condition that occurs in the setting of a thiamine (vitamin B1) deficiency and is characterized by a triad of mental status changes, ophthalmoplegia/nystagmus, and gait ataxia. However, the full triad is not present in every case of WE. Inadequately treated, patients may progress to suffer from Korsakoff syndrome, leaving patients with permanent memory impairment. == Etiology == The neurologic deficits associated with WE are caused by an inadequate supply of the vitamin thiamine to the brain. The absence of thiamine as an enzymatic cofactor leads to decreased energy availability and subsequent neurotoxicity. This neurotoxicity manifests acutely as ophthalmoplegia/nystagmus, ataxia, and mental status changes. == Risk Factors == WE is most commonly associated with chronic alcoholism but can be precipitated by any state in which thiamine consumption or absorption is reduced (e.g., anorexia, malabsorption or gastrointestinal/bariatric surgeries, starvation, hyperemesis gravidarum, parenteral feedings without vitamin replacement, or gastric malignancies). There may be a genetic disposition for the development of WE. == Pathophysiology == Thiamine is a co-factor for key metabolic enzymes. These include alpha-ketoglutarate dehydrogenase (involved in the Krebs’ cycle), transketolase (involved in the pentose phosphate pathway), and pyruvate dehydrogenase (involved in creating acetyl-CoA from pyruvate to fuel the Krebs’ cycle). Collective dysfunction of these enzymes due to thiamine deficiency leads to failure of oxidative metabolism, an ATP shortage, and eventually selective neuronal death. Additionally, in chronic alcoholics, thiamine transport pathways are thought to be impaired. This exacerbates symptoms in the setting of a deficiency, and leads to a greater incidence of residual deficits, progression to Korsakoff syndrome, and higher thiamine replacement dosing requirements. == Pathology == On autopsy, lesions tend to surround the third ventricle, fourth ventricle, and cerebral aqueduct. The mamillary bodies are almost always involved, and other sites of lesions can include the dorsomedial thalamus, locus ceruleus, periaqueductal gray, oculomotor nuclei, and vestibular nuclei. == Primary prevention == The risk of WE can be reduced by reducing or discontinuing excess alcohol consumption, maintaining a balanced diet, and adequately replacing vitamins in the setting of an anticipated deficiency (e.g. parenteral feeds, GI surgery). Additionally, WE can be precipitated iatrogenically in patients who are already deficient in vitamin B1 but are in advertantly given glucose (e.g., to treat dehydration) prior to parenteral thiamine replacement in the hospital setting. Prevention under these circumstances requires administering thiamine prior to glucose administration if there is any suspicion at all of WE. = Diagnosis = Diagnosis of WE is usually clinical, though a thiamine blood level via erythrocyte thiamine transketolase (ETKA) testing and neuroimaging can be supportive. Many patients present without all three classic signs (mental status changes, ophthalmoplegia, ataxia), and patients should be suspected of having WE if any of the following are present. If two of the following four signs (Caine’s criteria) are present, the diagnosis is likely: Dietary thiamine deficiency, oculomotor abnormalities (nystagmus or ophthalmoplegia), cerebellar dysfunction (ataxia), or either altered mental status or mild memory impairment. == Signs == The clinical signs of WE include ophthalmoplegia, gait ataxia, nystagmus, or mental status changes. There may be physical exam findings of dehydration or malnourishment. In addition, stupor, hypothermia, hypotension, vestibular dysfunction, and peripheral neuropathy can also be seen. = Management = Patients with suspected WE should be immediately treated with high dose parenteral thiamine. Most authors have recommended very high dose initial replacement regimen (e.g., IV thiamine 500mg TID for 2 days followed by 250mg daily for 5 days via IV or intramuscular administration). Patients should then be maintained on oral therapy until they are no longer at risk for thiamine deficiency. Additionally, thiamine should be administered concurrently with magnesium, an important cofactor. == Prognosis == With prompt thiamine replacement, WE can be reversible, but residual deficits may occur if treatment is delayed or if the dose is inadequate. Unfortunately, if treatment is delayed, progression to Korsakoff syndrome with permanent anterograde amnesia frequently occurs. Progression to Korsakoff syndrome is also more common in alcoholics. = References = 1. Galvin, R., Bråthen, G., Ivashynka, A., Hillbom, M., Tanasescu, R., & Leone, M. A. (2010). EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. European Journal of Neurology. https://doi.org/10.1111/j.1468-1331.2010.03153.x 2. Sechi G, Serra A. Wernicke’s encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol 2007; 6: 442–455. 3. So YT, MD. Wernicke Encephalopathy. Aminoff M, MD, Wilterdink J, MD, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com/contents/wernicke-encephalopathy?search=wernicke&source=search_result&selectedTitle=1~48&usage_type=default&display_rank=1#H14 (Accessed on March 14, 2019.) 4. Thomson AD, Guerrini I, Marshall EJ. The evolution and treatment of Korsakoff's syndrome: out of sight, out of mind?. Neuropsychol Rev. 2012;22(2):81-92.
Please note that all contributions to EyeWiki may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see EyeWiki:Copyrights for details). Do not submit copyrighted work without permission!

Cancel
Watch this page